| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 157, Issue 12 5503-5511, Copyright © 1996 by American Association of Immunologists
ARTICLES |
I Hakim, S Levy and R Levy
Division of Oncology, Department of Medicine, Stanford University Medical Center, CA 94305, USA.
The idiotypic determinants of B cell lymphoma provide a tumor-specific Ag and a target for immunotherapy. We have developed several generations of idiotype vaccines that were tested in an animal model, the 38C13 mouse B cell lymphoma. Initially we showed that effective tumor immunity was elicited by the syngeneic Id when it was conjugated to a carrier protein and mixed with an adjuvant. A subsequent generation of Id vaccines eliminated the need for a carrier protein and for an adjuvant by incorporating cytokines into fusion proteins containing the Id. A third generation of vaccines consisting of naked DNA encoding the Id-granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion proteins was equally effective in inducing tumor immunity. To determine whether Ig variable regions, in the absence of constant regions, could be immunotherapeutic in this model, we tested the use of single-chain Fv (scFv). scFv proteins, produced in bacteria, and naked DNA encoding scFv were used in this study. scFv was tested alone or fused to GM-CSF or an immunoenhancing peptide derived from IL- 1beta. Here we demonstrate that scFv-GM-CSF was effective only when injected as a protein, not as a DNA vaccine. In contrast, both scFv-IL- 1beta peptide fusion protein and naked DNA encoding it induced tumor immunity that protected mice from tumor challenge.
This article has been cited by other articles:
|
|
 |
|
  A. A. McCormick, S. Reddy, S. J. Reinl, T. I. Cameron, D. K. Czerwinkski, F. Vojdani, K. M. Hanley, S. J. Garger, E. L. White, J. Novak, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study PNAS, July 22, 2008; 105(29): 10131 - 10136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Fredriksen and B. Bogen Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences Blood, September 15, 2007; 110(6): 1797 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kanter, J. Yang, A. Voloshin, S. Levy, J. R. Swartz, and R. Levy Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines Blood, April 15, 2007; 109(8): 3393 - 3399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Muraro, A. Bondanza, M. Bellone, P. D. Greenberg, and C. Bonini Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses Blood, May 1, 2005; 105(9): 3596 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Timmerman, G. Singh, G. Hermanson, P. Hobart, D. K. Czerwinski, B. Taidi, R. Rajapaksa, C. B. Caspar, A. van Beckhoven, and R. Levy Immunogenicity of a Plasmid DNA Vaccine Encoding Chimeric Idiotype in Patients with B-Cell Lymphoma Cancer Res., October 15, 2002; 62(20): 5845 - 5852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Haupt, M. Roggendorf, and K. Mann The Potential of DNA Vaccination against Tumor-Associated Antigens for Antitumor Therapy Experimental Biology and Medicine, April 1, 2002; 227(4): 227 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biragyn, M. Surenhu, D. Yang, P. A. Ruffini, B. A. Haines, E. Klyushnenkova, J. J. Oppenheim, and L. W. Kwak Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens J. Immunol., December 1, 2001; 167(11): 6644 - 6653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Timmerman, C. B. Caspar, S. L. Lambert, A. D. Syrengelas, and R. Levy Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas Blood, March 1, 2001; 97(5): 1370 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. Maecker, G. Hansen, D. M. Walter, R. H. DeKruyff, S. Levy, and D. T. Umetsu Vaccination with Allergen-IL-18 Fusion DNA Protects Against, and Reverses Established, Airway Hyperreactivity in a Murine Asthma Model J. Immunol., January 15, 2001; 166(2): 959 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-H. Huang, P.-Y. Wu, C.-N. Lee, H.-I Huang, S.-L. Hsieh, J. Kung, and M.-H. Tao Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen Blood, December 1, 2000; 96(12): 3663 - 3670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Staats and F. A. Ennis Jr. IL-1 Is an Effective Adjuvant for Mucosal and Systemic Immune Responses When Coadministered with Protein Immunogens J. Immunol., May 15, 1999; 162(10): 6141 - 6147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Syrengelas and R. Levy DNA Vaccination Against the Idiotype of a Murine B Cell Lymphoma: Mechanism of Tumor Protection J. Immunol., April 15, 1999; 162(8): 4790 - 4795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. McNeel, K. Schiffman, and M. L. Disis Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Blood, April 15, 1999; 93(8): 2653 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. McCormick, M. H. Kumagai, K. Hanley, T. H. Turpen, I. Hakim, L. K. Grill, D. Tuse, S. Levy, and R. Levy Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants PNAS, January 19, 1999; 96(2): 703 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Britton, N. Meadows, D. A. Rathjen, D. R. Roach, and H. Briscoe A Tumor Necrosis Factor Mimetic Peptide Activates a Murine Macrophage Cell Line To Inhibit Mycobacterial Growth in a Nitric Oxide-Dependent Fashion Infect. Immun., May 1, 1998; 66(5): 2122 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Chow, B.-L. Chiang, Y.-L. Lee, W.-K. Chi, W.-C. Lin, Y.-T. Chen, and M.-H. Tao Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes J. Immunol., February 1, 1998; 160(3): 1320 - 1329. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
